Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax initiation optimization with obinutuzumab or acalabrutinib in previously untreated chronic lymphocytic leukemia
2024-512147-23-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label trial of venetoclax, obinutuzumab and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Incidence of treatment-emergent laboratory TLS or treatment-emergent hyperkalemia requiring clinical intervention and Reduction of tumor burden from baseline. Planned start Nov 2024; status: authorised.
02
Drugs
venetoclaxobinutuzumabacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-512147-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512147-23-00.